NR-546 Advanced Pharmacology Psychopharmacology for the Psychiatric- Mental Health Nurse Practitioner
Final Exam (Latest Update)
Question:
BPD I
Answer:
- manic mood dominates
- characterized by mood swings from extremely high (mania) to extremely
low (depression)
Question:
BPD II
Answer:
the presence or history of an MDD and at least one hypomanic episode.Symptoms last for at least 4 days but no longer than 7.
- / 4
Question:
Cyclothenia
Answer:
Chronic presentation of hypomanic and depressive symptoms but does not meet diagnostic criteria for a major depressive episode or manic/hypomanic episode.
Question:
decreased positive affect
Answer:
Depressed mood, loss of joy, lack of interest, loss of energy, decreased alertness, decreased self-confidence, and appetite changes are symptoms of this affect
Question:
increased negative affect
Answer:
depressed mood, guilt, anxiety/fear, hostility, irritability, loneliness, and appetite changes are symptoms of this affect
- / 4
Question:
Serotonin receptors
Answer:
90% are in the GI tract, 10% are in the brain
Question:
SARI MOA
Answer:
block 5HT 2A and 2C receptors allowing more serotonin to interact at postsynaptic 5HT 1A
Question:
Most common SARI
Answer:
trazadone
Question:
Trazadone
Answer:
This antidepressant causes sedation, drowsiness, blurred vision, constipation, dry mouth, and priapism. Can also be used to treat insomnia and anxiety. 3 / 4
Question:
mirtazapine (remeron)
Answer:
Antidepressant that is a serotonin, NE, and alpha2 receptor AGONIST that is assoc w/ drowsiness/sedation (useful for pt with insomnia), and can cause increased appetite and weight gain (appropriate for pt who loses weight d/t depression).
Question:
Vilazodone (Viibryd)
Answer:
Antidepressant that is a serotonin multimodal (SMM)/serotonin partial agonist reuptake inhibitor (SPARI) that inhibits serotonin reuptake with partial 5HT-1A agonism and is appropriate for depression/comorbid anxiety.Its action is similar to a combo of SSRI and bus-irons.
Question:
Vortioxetine (Trintellix)
Answer:
SMM antidepressant that acts as SSRI plus 5HT-1A partial agonist and improves depression related cognition.
- / 4